We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FXNC:NASDAQFirst National Corporation Analysis

Data as of 2026-04-05 - not real-time

$27.15

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

FXNC is trading just above its 20‑day SMA (26.42) and 50‑day SMA (26.83), with the price (27.15) comfortably above the 24.16 support level and below the 28.00 resistance, suggesting a stable range. The MACD histogram is positive (0.12) and the signal line is bearish, producing a bullish MACD reading, while the RSI sits at 58, indicating modest upside momentum without being overbought. Volatility over the past 30 days is elevated at 22%, but the beta of 0.5 signals lower systematic risk compared to the market.
Fundamentally, the bank posted a 34% revenue growth year‑over‑year, trades at a forward PE of 10.8 versus an industry average of 16.6, and offers a 2.51% dividend yield with a modest 32% payout ratio, underscoring dividend sustainability. With $163 M in cash, $44 M of debt and a debt‑to‑equity of zero, the balance sheet is strong, and the DCF‑derived fair value of $85.15 implies the stock is deeply undervalued, even though the model’s near‑term upside estimate is modest at ~3%.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near short‑term SMAs with limited upside
  • Bullish MACD but decreasing volume suggests caution
  • Support level at 24.16 provides downside protection

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong 34% revenue growth and low forward PE relative to peers
  • Sustainable dividend yield of 2.51% with low payout ratio
  • Robust cash position and negligible debt enhance financial stability

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value of $85.15 indicates deep undervaluation
  • Low beta (0.5) and modest volatility reduce market‑wide risk
  • Consistent profitability metrics (ROE 10%, profit margin 20%) support long‑run earnings potential

Key Metrics & Analysis

Financial Health

Revenue Growth33.80%
Profit Margin20.35%
P/E Ratio13.9
ROE10.04%
ROA0.88%
P/B Ratio1.3
Op. Cash Flow$25.1M
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI58.2
Support$24.16
Resistance$28.00
MA 20$26.42
MA 50$26.83
MA 200$23.90
MACDBullish
VolumeDecreasing
Fear & Greed Index78.8

Valuation

Fair Value$85.15
Target Price$28.00
Upside/Downside3.13%
GradeUndervalued
TypeBlend
Dividend Yield2.51%

Risk Assessment

Beta0.65
Volatility22.06%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.